Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 19 entries
Sorted by: Best Match Show Resources per page
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.

Lancet (London, England)

Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, Harris RA, Hutton D, Jacobsen N, Joyce K, Kaminski R, Libri V, Middleditch A, McCullagh L, Moran E, Phillipson A, Price E, Ryan J, Thirard R, Todd R, Snape MD, Tucker D, Williams RL, Nguyen-Van-Tam JS, Finn A, Rogers CA.
PMID: 34774197
Lancet. 2021 Nov 11; doi: 10.1016/S0140-6736(21)02329-1. Epub 2021 Nov 11.

BACKGROUND: Concomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of concomitant administration of ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine.METHODS: In this multicentre, randomised, controlled, phase 4...

Cite
Lazarus R, Baos S, Cappel-Porter H, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021;doi: 10.1016/S0140-6736(21)02329-1.
Lazarus, R., Baos, S., Cappel-Porter, H., Carson-Stevens, A., Clout, M., Culliford, L., Emmett, S. R., Garstang, J., Gbadamoshi, L., Hallis, B., Harris, R. A., Hutton, D., Jacobsen, N., Joyce, K., Kaminski, R., Libri, V., Middleditch, A., McCullagh, L., Moran, E., Phillipson, A., Price, E., Ryan, J., Thirard, R., Todd, R., Snape, M. D., Tucker, D., Williams, R. L., Nguyen-Van-Tam, J. S., Finn, A., Rogers, C. A. (2021). Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet (London, England), . https://doi.org/10.1016/S0140-6736(21)02329-1
Lazarus, Rajeka, et al. "Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial." Lancet (London, England) vol. (2021). doi: https://doi.org/10.1016/S0140-6736(21)02329-1
Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, Harris RA, Hutton D, Jacobsen N, Joyce K, Kaminski R, Libri V, Middleditch A, McCullagh L, Moran E, Phillipson A, Price E, Ryan J, Thirard R, Todd R, Snape MD, Tucker D, Williams RL, Nguyen-Van-Tam JS, Finn A, Rogers CA. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021 Nov 11; doi: 10.1016/S0140-6736(21)02329-1. Epub 2021 Nov 11. PMID: 34774197; PMCID: PMC8585490.
Copy Download .nbib Format: NLM
A higher-protein nut-based snack product suppresses glycaemia and decreases glycaemic response to co-ingested carbohydrate in an overweight prediabetic Asian Chinese cohort: the Tū Ora postprandial RCT.

Journal of nutritional science

Lu LW, Silvestre MP, Sequeira IR, Plank LD, Foster M, Middleditch N, Acevedo-Fani A, Hollingsworth KG, Poppitt SD.
PMID: 34094511
J Nutr Sci. 2021 Apr 23;10:e30. doi: 10.1017/jns.2021.20. eCollection 2021.

Nut-based products may aid low-glycaemic dietary strategies that are important for diabetes prevention in populations at increased risk of dysglycaemia, such as Asian Chinese. This randomised cross-over trial assessed the postprandial glycaemic response (0-120 min) of a higher-protein nut-based...

Cite
Lu LW, Silvestre MP, Sequeira IR, et al. A higher-protein nut-based snack product suppresses glycaemia and decreases glycaemic response to co-ingested carbohydrate in an overweight prediabetic Asian Chinese cohort: the Tū Ora postprandial RCT. J Nutr Sci. 2021;10:e30doi: 10.1017/jns.2021.20.
Lu, L. W., Silvestre, M. P., Sequeira, I. R., Plank, L. D., Foster, M., Middleditch, N., Acevedo-Fani, A., Hollingsworth, K. G., & Poppitt, S. D. (2021). A higher-protein nut-based snack product suppresses glycaemia and decreases glycaemic response to co-ingested carbohydrate in an overweight prediabetic Asian Chinese cohort: the Tū Ora postprandial RCT. Journal of nutritional science, 10e30. https://doi.org/10.1017/jns.2021.20
Lu, Louise W, et al. "A higher-protein nut-based snack product suppresses glycaemia and decreases glycaemic response to co-ingested carbohydrate in an overweight prediabetic Asian Chinese cohort: the Tū Ora postprandial RCT." Journal of nutritional science vol. 10 (2021): e30. doi: https://doi.org/10.1017/jns.2021.20
Lu LW, Silvestre MP, Sequeira IR, Plank LD, Foster M, Middleditch N, Acevedo-Fani A, Hollingsworth KG, Poppitt SD. A higher-protein nut-based snack product suppresses glycaemia and decreases glycaemic response to co-ingested carbohydrate in an overweight prediabetic Asian Chinese cohort: the Tū Ora postprandial RCT. J Nutr Sci. 2021 Apr 23;10:e30. doi: 10.1017/jns.2021.20. eCollection 2021. PMID: 34094511; PMCID: PMC8141680.
Copy Download .nbib Format: NLM
Utility of the .

ACS omega

Lin B, Daniels BJ, Middleditch MJ, Furkert DP, Brimble MA, Bong J, Stephens JM, Loomes KM.
PMID: 32337448
ACS Omega. 2020 Apr 08;5(15):8858-8866. doi: 10.1021/acsomega.0c00486. eCollection 2020 Apr 21.

Manuka honey is a premium food product with unique antimicrobial bioactivity. Concerns with mislabeled manuka honey require robust assays to determine authenticity. Lepteridine is a

Cite
Lin B, Daniels BJ, Middleditch MJ, et al. Utility of the . ACS Omega. 2020;5(15):8858-8866doi: 10.1021/acsomega.0c00486.
Lin, B., Daniels, B. J., Middleditch, M. J., Furkert, D. P., Brimble, M. A., Bong, J., Stephens, J. M., & Loomes, K. M. (2020). Utility of the . ACS omega, 5(15), 8858-8866. https://doi.org/10.1021/acsomega.0c00486
Lin, Bin, et al. "Utility of the ." ACS omega vol. 5,15 (2020): 8858-8866. doi: https://doi.org/10.1021/acsomega.0c00486
Lin B, Daniels BJ, Middleditch MJ, Furkert DP, Brimble MA, Bong J, Stephens JM, Loomes KM. Utility of the . ACS Omega. 2020 Apr 08;5(15):8858-8866. doi: 10.1021/acsomega.0c00486. eCollection 2020 Apr 21. PMID: 32337448; PMCID: PMC7178798.
Copy Download .nbib Format: NLM
Mass spectra of prostaglandins: II. Trimethylsilyl and alkyloxime-trimethylsilyl derivatives of prostaglandins B1 and B2.

Lipids

Middleditch BS, Desiderio DM.
PMID: 27519877
Lipids. 1973 May;8(5):267-70. doi: 10.1007/BF02531903.

The mass spectra of the trimethylsilyl ester trimethylsilyl ether derivatives of prostaglandins B1 and B2, and of theirO-ethyl andO-methyl oximes are reported and discussed. The high resolution spectra of these compounds are also considered. These spectra are compared with...

Cite
Middleditch BS, Desiderio DM. Mass spectra of prostaglandins: II. Trimethylsilyl and alkyloxime-trimethylsilyl derivatives of prostaglandins B1 and B2. Lipids. 1973;8(5):267-70doi: 10.1007/BF02531903.
Middleditch, B. S., & Desiderio, D. M. (1973). Mass spectra of prostaglandins: II. Trimethylsilyl and alkyloxime-trimethylsilyl derivatives of prostaglandins B1 and B2. Lipids, 8(5), 267-70. https://doi.org/10.1007/BF02531903
Middleditch, B S, and Desiderio, D M. "Mass spectra of prostaglandins: II. Trimethylsilyl and alkyloxime-trimethylsilyl derivatives of prostaglandins B1 and B2." Lipids vol. 8,5 (1973): 267-70. doi: https://doi.org/10.1007/BF02531903
Middleditch BS, Desiderio DM. Mass spectra of prostaglandins: II. Trimethylsilyl and alkyloxime-trimethylsilyl derivatives of prostaglandins B1 and B2. Lipids. 1973 May;8(5):267-70. doi: 10.1007/BF02531903. PMID: 27519877.
Copy Download .nbib Format: NLM
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.

Lancet (London, England)

Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, Harris RA, Hutton D, Jacobsen N, Joyce K, Kaminski R, Libri V, Middleditch A, McCullagh L, Moran E, Phillipson A, Price E, Ryan J, Thirard R, Todd R, Snape MD, Tucker D, Williams RL, Nguyen-Van-Tam JS, Finn A, Rogers CA.
PMID: 34774197
Lancet. 2021 Dec 18;398(10318):2277-2287. doi: 10.1016/S0140-6736(21)02329-1. Epub 2021 Nov 11.

BACKGROUND: Concomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of concomitant administration of ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine.METHODS: In this multicentre, randomised, controlled, phase 4...

Cite
Lazarus R, Baos S, Cappel-Porter H, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021;398(10318):2277-2287doi: 10.1016/S0140-6736(21)02329-1.
Lazarus, R., Baos, S., Cappel-Porter, H., Carson-Stevens, A., Clout, M., Culliford, L., Emmett, S. R., Garstang, J., Gbadamoshi, L., Hallis, B., Harris, R. A., Hutton, D., Jacobsen, N., Joyce, K., Kaminski, R., Libri, V., Middleditch, A., McCullagh, L., Moran, E., Phillipson, A., Price, E., Ryan, J., Thirard, R., Todd, R., Snape, M. D., Tucker, D., Williams, R. L., Nguyen-Van-Tam, J. S., Finn, A., Rogers, C. A. (2021). Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet (London, England), 398(10318), 2277-2287. https://doi.org/10.1016/S0140-6736(21)02329-1
Lazarus, Rajeka, et al. "Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial." Lancet (London, England) vol. 398,10318 (2021): 2277-2287. doi: https://doi.org/10.1016/S0140-6736(21)02329-1
Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, Harris RA, Hutton D, Jacobsen N, Joyce K, Kaminski R, Libri V, Middleditch A, McCullagh L, Moran E, Phillipson A, Price E, Ryan J, Thirard R, Todd R, Snape MD, Tucker D, Williams RL, Nguyen-Van-Tam JS, Finn A, Rogers CA. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021 Dec 18;398(10318):2277-2287. doi: 10.1016/S0140-6736(21)02329-1. Epub 2021 Nov 11. PMID: 34774197; PMCID: PMC8585490.
Copy Download .nbib Format: NLM
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.

Lancet (London, England)

Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, Harris RA, Hutton D, Jacobsen N, Joyce K, Kaminski R, Libri V, Middleditch A, McCullagh L, Moran E, Phillipson A, Price E, Ryan J, Thirard R, Todd R, Snape MD, Tucker D, Williams RL, Nguyen-Van-Tam JS, Finn A, Rogers CA.
PMID: 34774197
Lancet. 2021 Dec 18;398(10318):2277-2287. doi: 10.1016/S0140-6736(21)02329-1. Epub 2021 Nov 11.

BACKGROUND: Concomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of concomitant administration of ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine.METHODS: In this multicentre, randomised, controlled, phase 4...

Cite
Lazarus R, Baos S, Cappel-Porter H, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021;398(10318):2277-2287doi: 10.1016/S0140-6736(21)02329-1.
Lazarus, R., Baos, S., Cappel-Porter, H., Carson-Stevens, A., Clout, M., Culliford, L., Emmett, S. R., Garstang, J., Gbadamoshi, L., Hallis, B., Harris, R. A., Hutton, D., Jacobsen, N., Joyce, K., Kaminski, R., Libri, V., Middleditch, A., McCullagh, L., Moran, E., Phillipson, A., Price, E., Ryan, J., Thirard, R., Todd, R., Snape, M. D., Tucker, D., Williams, R. L., Nguyen-Van-Tam, J. S., Finn, A., Rogers, C. A. (2021). Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet (London, England), 398(10318), 2277-2287. https://doi.org/10.1016/S0140-6736(21)02329-1
Lazarus, Rajeka, et al. "Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial." Lancet (London, England) vol. 398,10318 (2021): 2277-2287. doi: https://doi.org/10.1016/S0140-6736(21)02329-1
Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, Harris RA, Hutton D, Jacobsen N, Joyce K, Kaminski R, Libri V, Middleditch A, McCullagh L, Moran E, Phillipson A, Price E, Ryan J, Thirard R, Todd R, Snape MD, Tucker D, Williams RL, Nguyen-Van-Tam JS, Finn A, Rogers CA. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021 Dec 18;398(10318):2277-2287. doi: 10.1016/S0140-6736(21)02329-1. Epub 2021 Nov 11. PMID: 34774197; PMCID: PMC8585490.
Copy Download .nbib Format: NLM
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.

Lancet (London, England)

Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, Harris RA, Hutton D, Jacobsen N, Joyce K, Kaminski R, Libri V, Middleditch A, McCullagh L, Moran E, Phillipson A, Price E, Ryan J, Thirard R, Todd R, Snape MD, Tucker D, Williams RL, Nguyen-Van-Tam JS, Finn A, Rogers CA.
PMID: 34774197
Lancet. 2021 Dec 18;398(10318):2277-2287. doi: 10.1016/S0140-6736(21)02329-1. Epub 2021 Nov 11.

BACKGROUND: Concomitant administration of COVID-19 and influenza vaccines could reduce burden on health-care systems. We aimed to assess the safety of concomitant administration of ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine.METHODS: In this multicentre, randomised, controlled, phase 4...

Cite
Lazarus R, Baos S, Cappel-Porter H, et al. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021;398(10318):2277-2287doi: 10.1016/S0140-6736(21)02329-1.
Lazarus, R., Baos, S., Cappel-Porter, H., Carson-Stevens, A., Clout, M., Culliford, L., Emmett, S. R., Garstang, J., Gbadamoshi, L., Hallis, B., Harris, R. A., Hutton, D., Jacobsen, N., Joyce, K., Kaminski, R., Libri, V., Middleditch, A., McCullagh, L., Moran, E., Phillipson, A., Price, E., Ryan, J., Thirard, R., Todd, R., Snape, M. D., Tucker, D., Williams, R. L., Nguyen-Van-Tam, J. S., Finn, A., Rogers, C. A. (2021). Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet (London, England), 398(10318), 2277-2287. https://doi.org/10.1016/S0140-6736(21)02329-1
Lazarus, Rajeka, et al. "Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial." Lancet (London, England) vol. 398,10318 (2021): 2277-2287. doi: https://doi.org/10.1016/S0140-6736(21)02329-1
Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, Harris RA, Hutton D, Jacobsen N, Joyce K, Kaminski R, Libri V, Middleditch A, McCullagh L, Moran E, Phillipson A, Price E, Ryan J, Thirard R, Todd R, Snape MD, Tucker D, Williams RL, Nguyen-Van-Tam JS, Finn A, Rogers CA. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial. Lancet. 2021 Dec 18;398(10318):2277-2287. doi: 10.1016/S0140-6736(21)02329-1. Epub 2021 Nov 11. PMID: 34774197; PMCID: PMC8585490.
Copy Download .nbib Format: NLM
Itaconate is a covalent inhibitor of the .

RSC medicinal chemistry

Kwai BXC, Collins AJ, Middleditch MJ, Sperry J, Bashiri G, Leung IKH.
PMID: 34046597
RSC Med Chem. 2020 Oct 19;12(1):57-61. doi: 10.1039/d0md00301h. eCollection 2021 Jan 01.

Itaconate is a mammalian antimicrobial metabolite that inhibits the isocitrate lyases (ICLs) of

Cite
Kwai BXC, Collins AJ, Middleditch MJ, et al. Itaconate is a covalent inhibitor of the . RSC Med Chem. 2020;12(1):57-61doi: 10.1039/d0md00301h.
Kwai, B. X. C., Collins, A. J., Middleditch, M. J., Sperry, J., Bashiri, G., & Leung, I. K. H. (2021). Itaconate is a covalent inhibitor of the . RSC medicinal chemistry, 12(1), 57-61. https://doi.org/10.1039/d0md00301h
Kwai, Brooke X C, et al. "Itaconate is a covalent inhibitor of the ." RSC medicinal chemistry vol. 12,1 (2021): 57-61. doi: https://doi.org/10.1039/d0md00301h
Kwai BXC, Collins AJ, Middleditch MJ, Sperry J, Bashiri G, Leung IKH. Itaconate is a covalent inhibitor of the . RSC Med Chem. 2020 Oct 19;12(1):57-61. doi: 10.1039/d0md00301h. eCollection 2021 Jan 01. PMID: 34046597; PMCID: PMC8130629.
Copy Download .nbib Format: NLM
Characterization of proteomic changes in cardiac mitochondria in streptozotocin-diabetic rats using iTRAQ™ isobaric tags.

Proteomics. Clinical applications

Jüllig M, Hickey AJ, Middleditch MJ, Crossman DJ, Lee SC, Cooper GJ.
PMID: 21136708
Proteomics Clin Appl. 2007 Jun;1(6):565-76. doi: 10.1002/prca.200600831.

Diabetes now affects more than 5% of the world's population and heart failure is the most common cause of death amongst diabetic patients. Accumulating evidence supports a view that myocardial mitochondrial structural and functional changes are central to the...

Cite
Jüllig M, Hickey AJ, Middleditch MJ, et al. Characterization of proteomic changes in cardiac mitochondria in streptozotocin-diabetic rats using iTRAQ™ isobaric tags. Proteomics Clin Appl. 2007;1(6):565-76doi: 10.1002/prca.200600831.
Jüllig, M., Hickey, A. J., Middleditch, M. J., Crossman, D. J., Lee, S. C., & Cooper, G. J. (2007). Characterization of proteomic changes in cardiac mitochondria in streptozotocin-diabetic rats using iTRAQ™ isobaric tags. Proteomics. Clinical applications, 1(6), 565-76. https://doi.org/10.1002/prca.200600831
Jüllig, Mia, et al. "Characterization of proteomic changes in cardiac mitochondria in streptozotocin-diabetic rats using iTRAQ™ isobaric tags." Proteomics. Clinical applications vol. 1,6 (2007): 565-76. doi: https://doi.org/10.1002/prca.200600831
Jüllig M, Hickey AJ, Middleditch MJ, Crossman DJ, Lee SC, Cooper GJ. Characterization of proteomic changes in cardiac mitochondria in streptozotocin-diabetic rats using iTRAQ™ isobaric tags. Proteomics Clin Appl. 2007 Jun;1(6):565-76. doi: 10.1002/prca.200600831. PMID: 21136708.
Copy Download .nbib Format: NLM
Towards energetically viable asymmetric deprotonations: selectivity at more elevated temperatures with C2-symmetric magnesium bisamides.

Chemical communications (Cambridge, England)

Bennie LS, Kerr WJ, Middleditch M, Watson AJ.
PMID: 21243164
Chem Commun (Camb). 2011 Feb 28;47(8):2264-6. doi: 10.1039/c0cc04939e. Epub 2011 Jan 18.

A novel chiral magnesium bisamide has enabled the development of effective asymmetric deprotonation protocols at substantially more elevated temperatures. This new, structurally simple, C(2)-symmetric magnesium complex displays excellent levels of asymmetric efficiency and energy reduction in the synthesis of...

Cite
Bennie LS, Kerr WJ, Middleditch M, et al. Towards energetically viable asymmetric deprotonations: selectivity at more elevated temperatures with C2-symmetric magnesium bisamides. Chem Commun (Camb). 2011;47(8):2264-6doi: 10.1039/c0cc04939e.
Bennie, L. S., Kerr, W. J., Middleditch, M., & Watson, A. J. (2011). Towards energetically viable asymmetric deprotonations: selectivity at more elevated temperatures with C2-symmetric magnesium bisamides. Chemical communications (Cambridge, England), 47(8), 2264-6. https://doi.org/10.1039/c0cc04939e
Bennie, Linsey S, et al. "Towards energetically viable asymmetric deprotonations: selectivity at more elevated temperatures with C2-symmetric magnesium bisamides." Chemical communications (Cambridge, England) vol. 47,8 (2011): 2264-6. doi: https://doi.org/10.1039/c0cc04939e
Bennie LS, Kerr WJ, Middleditch M, Watson AJ. Towards energetically viable asymmetric deprotonations: selectivity at more elevated temperatures with C2-symmetric magnesium bisamides. Chem Commun (Camb). 2011 Feb 28;47(8):2264-6. doi: 10.1039/c0cc04939e. Epub 2011 Jan 18. PMID: 21243164.
Copy Download .nbib Format: NLM
The application of eDNA for monitoring of the Great Crested Newt in the UK.

Ecology and evolution

Rees HC, Bishop K, Middleditch DJ, Patmore JR, Maddison BC, Gough KC.
PMID: 25505530
Ecol Evol. 2014 Nov;4(21):4023-32. doi: 10.1002/ece3.1272. Epub 2014 Sep 30.

Current ecological surveys for great crested newts are time-consuming and expensive and can only be carried out within a short survey window. Additional survey methods which would facilitate the detection of rare or protected species such as the great...

Cite
Rees HC, Bishop K, Middleditch DJ, et al. The application of eDNA for monitoring of the Great Crested Newt in the UK. Ecol Evol. 2014;4(21):4023-32doi: 10.1002/ece3.1272.
Rees, H. C., Bishop, K., Middleditch, D. J., Patmore, J. R., Maddison, B. C., & Gough, K. C. (2014). The application of eDNA for monitoring of the Great Crested Newt in the UK. Ecology and evolution, 4(21), 4023-32. https://doi.org/10.1002/ece3.1272
Rees, Helen C, et al. "The application of eDNA for monitoring of the Great Crested Newt in the UK." Ecology and evolution vol. 4,21 (2014): 4023-32. doi: https://doi.org/10.1002/ece3.1272
Rees HC, Bishop K, Middleditch DJ, Patmore JR, Maddison BC, Gough KC. The application of eDNA for monitoring of the Great Crested Newt in the UK. Ecol Evol. 2014 Nov;4(21):4023-32. doi: 10.1002/ece3.1272. Epub 2014 Sep 30. PMID: 25505530; PMCID: PMC4242556.
Copy Download .nbib Format: NLM
Artifacts in chromatography: an overview.

Journal of chromatographic science

Middleditch BS, Zlatkis A.
PMID: 3323218
J Chromatogr Sci. 1987 Dec;25(12):547-51. doi: 10.1093/chromsci/25.12.547.

A brief overview of the field of analytical artifacts is provided, with examples of solvent impurities, stabilizers, polymer additives, and problems relating to Teflon, glassware, and laboratory contaminants.

Cite
Middleditch BS, Zlatkis A. Artifacts in chromatography: an overview. J Chromatogr Sci. 1987;25(12):547-51doi: 10.1093/chromsci/25.12.547.
Middleditch, B. S., & Zlatkis, A. (1987). Artifacts in chromatography: an overview. Journal of chromatographic science, 25(12), 547-51. https://doi.org/10.1093/chromsci/25.12.547
Middleditch, B S, and Zlatkis, A. "Artifacts in chromatography: an overview." Journal of chromatographic science vol. 25,12 (1987): 547-51. doi: https://doi.org/10.1093/chromsci/25.12.547
Middleditch BS, Zlatkis A. Artifacts in chromatography: an overview. J Chromatogr Sci. 1987 Dec;25(12):547-51. doi: 10.1093/chromsci/25.12.547. PMID: 3323218.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 19 entries